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Edited by Vladimir SkulachevAbstract Exposure to limiting oxygen in cells and tissues in-
duce the stabilization and transcriptional activation of the hy-
poxia-inducible factor 1 alpha (HIF-1a) protein, a key
regulator of the hypoxic response. Reactive oxygen species
(ROS) generation has been implicated in the stabilization of
HIF-1a during this response, but this is still a matter of some de-
bate. In this study we utilize a mitochondria-targeted antioxi-
dant, mitoubiquinone (MitoQ), and examine its eﬀects on the
hypoxic stabilization of HIF-1a. Our results show that under
conditions of reduced oxygen (3% O2), MitoQ ablated the hyp-
oxic induction of ROS generation and destabilized HIF-1a pro-
tein. This in turn led to an abrogation of HIF-1 transcriptional
activity. Normoxic stabilization of HIF-1a, on the other hand,
was unchanged in the presence of MitoQ suggesting that ROS
were not involved. This study strongly suggests that mitochon-
drial ROS contribute to the hypoxic stabilization of HIF-1a.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Hypoxia; Antioxidant; Reactive oxygen species;
Hypoxia-inducible factor-1a; Mitoubiquinone1. Introduction
The transcription factor HIF-1 (hypoxia inducible factor-1)
occupies a central position in oxygen homeostasis and is con-
sidered to be a key regulator in cellular responses to reduced
oxygen concentrations. The practicalities of the HIF system
have been the subject of regular reviews (for recent additions
see [1,2]). In brief, HIF-1 is a heterodimer composed of an oxy-
gen sensitive a subunit and a constitutively active b subunit [3].
In normoxic conditions for cell culture (ca. 21% oxygen) theAbbreviations: HIF, hypoxia-inducible factor; PHD, prolyl hydroxy-
lase; PHD3, prolyl hydroxylase 3; RT-PCR, reverse-transcription PCR;
SDS–PAGE, SDS–polyacrylamide gel electrophoresis; HRE, hypoxia
responsive element; pVHL, von Hippel-Lindau protein; MitoQ, mito-
ubiquinone
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sequent proteosomal degradation following hydroxylation of
proline [4,5] and asparagine residues [6]. Under conditions of
reduced oxygen (from 0 to 5%) this post-translational degrada-
tion is inhibited, possibly due to reduced binding of oxygen to
HIF-prolyl hydroxylase (PHD) enzymes that require oxygen
for their function. Thus hypoxic conditions lead to a stabiliza-
tion of HIF-1a protein which can then transactivate down-
stream HIF-target genes. Recently, it has been described that
PHD gene products, themselves, are subject to hypoxic regula-
tion via HIF-1 [7] and thus contribute to a growing under-
standing of this central pathway [8].
There is accumulating evidence for the importance of reac-
tive oxygen species (ROS) as secondary messengers in a variety
of cellular situations [9]. Redox signaling of HIF-1a is an emo-
tive subject in the literature [10] and the argument for ROS sig-
naling to this protein is not entirely clear. Even more so, the
contribution of mitochondrial-derived ROS is debated
[11,12] with evidence for [13–15] and against [16] a mitochon-
drial-ROS signal. Often these contradictory reports result from
studies utilizing diﬀerent broad-range antioxidants and also
the employment of rho (0) cell lines devoid of mitochondrial
DNA [17]. These rho (0) cells which have been depleted of
mitochondrial DNA by long term incubation with the terato-
gen ethidium bromide lack a functioning electron transport
chain [18], the major site for ROS production. It is clear, how-
ever, that loss of mitochondrial DNA can change the expres-
sion of a number of genes [19] and inﬂuence cross talk
between mitochondria and the nucleus [20]. This, in turn,
may have ROS-independent eﬀects on HIF-1a expression
[16] and also oxygen consumption [15]. Two commonly used
generic antioxidants for the study of HIF-1 stabilization are
N-acetyl-L-cysteine (NAC) and pyrrolidine carbonate (PDTC).
NAC, apart from its direct role as an antioxidant, can raise
intracellular concentrations of cysteine and thus increase avail-
able glutathione (GSH). GSH can then detoxify ROS via the
glutathione-peroxidase coupled reaction. NAC is, however, a
rather poor scavenger of superoxide [21] and the reaction be-
tween NAC and hydrogen peroxide is slow and may not be sig-
niﬁcant. Also, at the rather high concentrations of NAC
normally used in studies (in the millimolar range) NAC has
the potential to inhibit multiple MAP kinase pathways [22].
PDTC possesses both antioxidant and pro-oxidant character-
istics [23], and can directly increase GSH oxidation, thusblished by Elsevier B.V. All rights reserved.
2670 A. Sanjua´n-Pla et al. / FEBS Letters 579 (2005) 2669–2674lowering the GSH/GSSG ratio [24]. PDTC, however, is also re-
ported to have several distinct targets in cells [22] and any
PDTC-mediated eﬀect on HIF-1a expression may not be di-
rectly linked to its role as an antioxidant.
Recently, a ubiquinone derivative, mitoubiquinone (MitoQ),
[25] has been developed in which ubiquinone is covalently
linked to a triphenylphosphonium (TPP) cation, allowing a
several-hundred fold accumulation within mitochondria. The
active antioxidant form of MitoQ is the reduced ubiquinol
form and this is regenerated by the electron transport chain,
and can selectively block mitochondrial oxidative damage by
detoxifying ROS [26–29]. This selective accumulation within
mitochondria thus makes MitoQ a useful tool to study mito-
chondrial-derived ROS and their potential signaling properties
during hypoxia.
In an attempt to resolve the issue of whether or not mito-
chondrial-derived ROS are involved in hypoxic signaling of
HIF-1a, we took advantage of this selective antioxidant,
and here we describe that indeed ROS are required for the
post-transcriptional stabilization of HIF-1a during hypoxic
incubation of cells. We also demonstrate that the downstream
activation of HIF-1a target genes is also perturbed in the pres-
ence of MitoQ. Normoxic stabilization of HIF-1a, on the
other hand, does not appear to require ROS. To our knowl-
edge this is the ﬁrst presentation on the use of a selective anti-
oxidant in studying the hypoxia-response pathway, and
underscores the contention that mitochondrial-derived ROS
are important signals during the cellular response to limiting
oxygen environments.2. Materials and methods
2.1. Reagents and cell culture
Culture media and fetal bovine serum were from Invitrogen Life
Technologies (Carlsbad, CA). MitoQ was synthesized as described
[25]. The proteosomal inhibitor MG132 was purchased from Calbio-
chem–Novabiochem Corp. (La Jolla, CA). All remaining chemicals,
unless otherwise noted, were from Sigma Chemical Co. (St. Louis,
MI). Speciﬁc cell treatment conditions are cited in the ﬁgure legends.
A human hepatoblastoma cell line Hep3B (ATCC HB-8064) was
routinely maintained in MEM supplemented with 10% fetal bovine ser-
um, L-glutamine (2 mM), non-essential amino acids, and sodium pyru-
vate (1 mM), at 37 C in a humidiﬁed environment of 5% CO2–95%
air. The ﬁbrosarcoma cell line HT1080 (ATCC CCL-121) and the
pVHL deﬁcient renal clear cell carcinoma cell lines 786-0 (over-
expressing either wild-type VHL+ or mutant VHL) were routinely
maintained in DMEM supplemented with 10% fetal bovine serum
and 2 mM sodium pyruvate. The 786-0 cells also received G418 at
100 lg/ml. All cultures were supplemented with penicillin and strepto-
mycin and were used for experiments when the cultures were approx-
imately 60% conﬂuent. Cell exposure to hypoxia was carried out in a
humidiﬁed environment of 3% O2, 5% CO2 and 92% N2. After the indi-
cated times, cells were processed for Western blot or reverse transcrip-
tion-polymerase chain (RT-PCR). Cell viability in the presence of
MitoQ was assessed using the tetrazolium salts-based XTT Cell Prolif-
eration Kit II (Roche Diagnostics, Mannheim, Germany).
2.2. RNA extraction and RT-PCR
Total RNA was isolated in cells harvested from 6-well dishes or T-25
cm2 culture ﬂasks using the RNeasy Mini kit from Qiagen (Valencia,
CA). Total cellular RNA (1 lg) was reverse transcribed with 100 U
of SuperScripte II reverse transcriptase (Invitrogen), using an
oligo-dT primer according to the manufacturers protocol. The
following forward and reverse primers were used: for human PHD3
5 0-GACCAGATCACGTGGATCGG-3 0 and 5 0-TCAGTCTTCAGT-
GAGGGCAGA-3 0 (GenBank NM_022073); for human HIF-1a 5 0-CACAGCCTGGATATGAA-3 0 and 5 0-GAATTCTTGGTGTTAT-
ATATG-3 0[30]; for Aldolase 5 0-CACTGGGATCACCTTCCTGT-30
and 5 0-ACGACACCACACACCACTGT-3 0 [31]; for human actin
5 0-TGGCACCACACCTTCTACAATGAGC-3 0 and 5 0-GCACAGC-
TTCTCCTTAATGTCACGC-3 0 (GenBank NM_001101). The PCR
conditions were established in pilot experiments such that linear
reaction rates were obtained, and all PCR products were sequenced
for veriﬁcation.
2.3. Western blotting analysis
Preparation of total protein extracts was carried out as described
[32]. Brieﬂy, after treatments, cell were quickly washed in ice-cold
PBS supplemented with phosphatase inhibitors (10 mM NaF, 10 mM
b-glycerophosphate, 10 mM p-nitrophenyl phosphate, and 1 mM
NaVO3) and a protease-inhibitor cocktail (Roche Diagnostics). Cells
were lysed and cleared by centrifugation. Protein concentrations were
determined with the Pierce BCA protein assay kit (Pierce Chemicals,
Boulder, CO) using BSA to generate a standard curve. An equal
amount of each protein sample (30 lg) was resolved by SDS–poly-
acrylamide gel electrophoresis (SDS–PAGE), transferred to nitrocellu-
lose membranes, and probed with anti-HIF-1a monoclonal Ab (BD
Transduction Labs, Lexington, KY), anti-PHD3 polyclonal Ab
(Novus Biologicals, Littleton, CO), and anti-tubulin monoclonal Ab
(Sigma). Peroxidase-coupled secondary antibodies were detected by
the enhanced Chemiluminescence (ECL) method from Amersham
(Amerham Pharmacia Biotech, UK).
2.4. Reporter gene assays
An HRE vector (pHRE-1), containing three copies of a synthetic oli-
gonucleotide of the minimal PGK-1 HRE cloned upstream of an SV40
minimal promoter (in the pGL3 vector, Promega) was a kind gift from
Dr. Kaye Williams (University of Manchester, UK). Transient co-
transfection assays of this reporter (200 ng) plus pHTK-RL (contain-
ing a thymidine kinase promoter upstream of Renilla reiformis,
75 ng) was carried out in 24-well plates containing 1 · 105 cells. Twenty
four hours after transfection, cells were placed in hypoxia for 16 h.
After treatment, the cells were harvested and luminescence was mea-
sured in a 96-well luminometer (Thermo Labsystems) using the STOP
AND GLOWe reporter assay system (Promega, Madison, WI).
2.5. Measurement of reactive oxygen species
For quantitative assessment of cellular ROS, more speciﬁcally
hydrogen peroxide (H2O2), we used the Amplex Red
R Hydrogen Per-
oxide/Peroxidase Assay kit (Molecular Probes, Eugene, OR), which
uses horseradish peroxidase to react with H2O2 in a 1:1 stoichiometry
to produce resoruﬁn. We measured resoruﬁn levels with a Multiskan
plate reader (Thermo Labsystems). A standard curve was generated
using H2O2, and results were expressed as nanomoles H2O2 per
5 · 104 cells.
2.6. Oxygen consumption
Endogenous respiration in whole cells was measured as described
previously [32]. Brieﬂy, exponentially growing cells were cultured in
the presence or absence of 1 lM MitoQ for 16 h, washed with PBS
and collected by trypsinization. After resuspension in Hanks balanced
salts solution (HBSS) the cells (3 · 106 cells/ml) were transferred to a
chamber equipped with an Oxygen electrode (Rank Bros., Bottisham,
UK). Oxygen consumption rates were measured over a 30 min period
and mitochondrial speciﬁcity was conﬁrmed by addition of 1 mM
KCN.3. Results and discussion
3.1. MitoQ destabilizes HIF-1a protein during hypoxia
It is well established that incubation of cells at reduced oxy-
gen concentrations leads to an increased level of HIF-1a pro-
tein due to decreased turnover, and consequently to an
upregulation of PHD3, an HIF-1a target gene (Fig. 1A). To
determine the eﬀects of MitoQ on HIF-1a expression, we ﬁrst
conducted a dose–response assay to examine the ability of
Fig. 1. Eﬀect of MitoQ on HIF-1a protein expression during hypoxia. (A) Protein levels of HIF-1a and PHD3 were assessed in Hep3B and HT1080
cells after exposure to 21% or 3% O2 for 4 h. (B and C) Hep3B or HT1080 cells were exposed to 3% O2 for 4 h in the presence of vehicle or MitoQ (1–
5 lM). MitoQ was added 15 min before exposure to hypoxia. (D) Hep3B cells were exposed to 3% O2 for 4 h in the presence of vehicle or TPP (1–5
lM). TPP was added 15 min before exposure to hypoxia. (E) Hep3B cells were pre-incubated at 21% O2 in the presence of vehicle or 1 or 2 lM
MitoQ for 6 h, followed by a medium change and exposure to 3% O2 for 3 h. (F) Hep3B cells were incubated at 21% O2 for 6 h in the presence of
vehicle or 1 M MitoQ and 20 lMMG132. (G) VHL defective 786-0 cells (VHL) were incubated for 12 h in the presence of vehicle or 1 lMMitoQ.
As a control, untreated 786-0 cells, expressing a functional VHL gene (VHL+) are shown also. Each experiment was performed at least three times
and representative data are shown.
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hypoxia in the presence of the antioxidant. Increasing concen-
trations of MitoQ from 1 to 5 lM dose-dependently decreased
the steady state level of HIF-1a during incubation at 3% oxy-
gen for 4 h, in both the Hep3B (Fig. 1B) and HT1080 (Fig. 1C)
cell lines, but was without eﬀect on a-tubulin levels. Protein
levels of PHD3 were also decreased in a concentration-depen-
dent fashion (Fig. 1B). Importantly, control experiments using
the lipophilic cation linker TPP, responsible for targeting Mi-
toQ to mitochondria, up to concentrations of 5 lM had no ef-
fect on HIF-1a expression during hypoxia, thus excluding a
non-speciﬁc eﬀect of the TPP group (Fig. 1D). Further dose–
response assays showed that the optimal MitoQ concentration
in these experiments was 1 lM (data not shown). As MitoQ is
speciﬁcally taken up by energized mitochondria, its accumula-
tion in these organelles increases with time until a steady state
distribution is reached. We therefore next determined if pre-
incubation with this compound, followed by a medium change
before exposure to hypoxia, would mimic the results obtained
when the antioxidant was added during the hypoxic episode.
Cells were thus ‘‘loaded’’ with either 1 or 2 lM MitoQ for
6 h, followed by a medium change, and then exposed to 3%
oxygen for 3 h. Cell death during this period, as assessed using
the XTT assay was less that 10% (data not shown). As revealed
in Fig. 1E the hypoxic expression of HIF-1a was blocked after
pre-treatment with MitoQ, thus showing that the antioxidant
was well retained within the cells.
Next, to test whether the inhibition of hypoxia-dependent
HIF-1a expression with MitoQ occurred at the level of protein
stabilization or protein synthesis, we employed the proteoso-
mal inhibitor MG132. In the presence of MG132 the continu-
ously synthesized HIF-1a accumulates during normoxia as
proteosomal destruction is halted. Thus, if MitoQ was acting
at the post-synthesis level it would have no eﬀect on the accu-
mulation of HIF-1a. The results shown in Fig. 1F demonstrate
that Hep3B cells incubated with MG132 accumulate HIF-1a
and the addition of MitoQ has no eﬀect in this process, reveal-
ing that MitoQ does not act at the level of protein synthesis.
Finally, to further conﬁrm this ﬁnding, we used the vonHippel-Lindau E3 ubiquitin ligase (pVHL) negative cell line
786-0, in which HIF-1a is stabilized in normoxia [33]. As
shown in Fig. 1G, addition of MitoQ to the culture medium
has no eﬀect on the expression of HIF-1a protein in this cell
line. Overall, these results indicate that loss of HIF-1a during
hypoxia, in the presence of MitoQ, is not due to a reduction in
protein synthesis, but rather point towards the destabilization
of the protein through disruption of mitochondrial-ROS.
3.2. Loss of HIF-1a transcriptional activity with MitoQ
Hypoxic stabilization of HIF-1a results in the activation of a
host of downstream hypoxia-responsive genes [2]. To ascertain
whether these genes were downregulated in the presence of
MitoQ, we repeated the dose–response experiment described
above, in the Hep3B cell line, and collected cells for RNA anal-
ysis. As seen in Fig. 2A, there was no change in HIF-1a
mRNA levels during incubation with MitoQ, suggesting that
the loss of HIF-1a protein was also not due to decreased tran-
scription of the gene. On the other hand, both known target
genes for HIF-1a, PHD3 and Aldolase, were downregulated,
in a concentration-dependent manner, upon incubation with
the antioxidant (Fig. 2A) with no eﬀect on actin mRNA. To
conﬁrm that the decrease in transcriptional activation of the
HIF-1 target genes was indeed the result of the absence of
HIF-1, we used a luciferase reporter vector utilizing a hypoxia
responsive element (HRE). Transient transfections of this re-
porter construct in Hep3B cells resulted in an increase in lucif-
erase protein upon incubation at 3% oxygen (Fig. 2B)
compared to normoxia, consistent with hypoxic activity. The
addition of 1 lMMitoQ during this hypoxic episode decreased
luciferase activity to basal levels, thus supporting the conten-
tion that HIF-1a mediated transcription is absent after block-
ade of ROS.
3.3. MitoQ does not impair respiration, but decreases ROS in
hypoxia
Recently, it has been described that loss of mitochondrial
electron transport chain (ETC) activity can result in the degra-
dation of HIF-1a during incubation of cells at reduced oxygen
Fig. 2. Eﬀect of MitoQ on HIF-1a and target gene expression during
hypoxia. (A) Hep3B cells were incubated in the presence of vehicle or
MitoQ (1–5 lM) for 6 h at 3% O2 before collection and RNA isolation.
mRNA species were quantiﬁed by RT-PCR and DNA products were
visualized with ethidium bromide on 2% agarose gels. This experiment
was performed three times and representative data are shown. (B)
Analysis of HIF-1a mediated reporter gene transcription. Hep3B cells
were co-transfected with pHTK-RL and pHRE-1 reporter vectors.
Twenty-four hours after transfection, cells were incubated for a further
16 h at 21% or 3% O2 in the presence of vehicle or 1 lM MitoQ. The
ratio of ﬁreﬂy to Renilla luciferase expression was then determined.
Results are representative of three independent experiments performed
in triplicate.
Fig. 3. MitoQ does not impede oxidative phosphorylation but
removes mitochondrial ROS. (A) Whole cell oxygen consumption in
Hep3B cells. Cells (3 · 106/ml) were re-suspended in HBSS after a pre-
incubation period of 16 h in medium with the addition of either 1 lM
MitoQ or vehicle. Oxygen levels were monitored over a 30 min period.
Graph shown is representative from three diﬀerent experiments.
Oxygen consumption rates were reported as 2.008 ± 0.06 and
1.97 ± 0.04 (nmol/min/106 cells) for vehicle and MitoQ respectively.
(B) Oxygen consumption was measured in Hep3B cells in the presence
or absence of 500 lM L-NAME (added 30 min before start of the
experiment). The result shown is representative from duplicate
experiments. (C) Cellular ROS, measured by H2O2, during a 4 h
incubation at 21% or 3% oxygen, plus or minus the addition of 0.5 or
1 lM MitoQ. MitoQ was added 15 min before the start of the
experiment.
2672 A. Sanjua´n-Pla et al. / FEBS Letters 579 (2005) 2669–2674levels [32]. The probable mechanism is the redistribution of
intracellular oxygen after ‘‘disruption’’ of the ETC by mito-
chondrial poisons or nitric oxide (NO), which in turn might
lead to oxygen availability for PHD activity [34]. As MitoQ
is targeted to the mitochondrion we wanted to assess whether
oxidative phosphorylation was perturbed in this situation. To
this end we measured oxygen consumption rates in whole cells
which had been pre-incubated for 16 h with 1 lM MitoQ. As
shown in Fig. 3A, there was no change in oxygen consumption
under these conditions, suggesting that MitoQ does not ob-
struct the ETC. To address the potential involvement of NO,
we measured oxygen consumption in Hep3B cells in the pres-
ence of the NO-synthase inhibitor L-NAME (N-nitro-L-argi-
nine methyl ester). Our results showed that oxygen
consumption in Hep3B cells was identical in the presence or
absence of 500 lM L-NAME (Fig. 3B), suggesting that NO
was not participating in this system. Lastly, using a quantita-
tive enzymatic assay for ROS [35] we measured the cumulative
cellular levels of H2O2 during incubation of cells at 3% oxygen
for 4 h (a time chosen to match HIF-1a stabilization studies)
with or without the addition of MitoQ. In line with a previous
report [27], addition of MitoQ blocked the hypoxic increase of
ROS in a dose-dependent manner (Fig. 3C). Fluorescence
staining of cells in similar experiments, using the ROS-reactive
dye 2 0,7 0-dichlorodihydroﬂuorescein diacetate revealed similar
results (data not shown).
Taken together, the results presented here are consistent
with the hypothesis that hypoxia increases the amount of mito-
chondrial-generated ROS, which in turns leads to a stabiliza-
tion of HIF-1a protein and activation of the hypoxia
response pathway. Scavenging of ROS, at the source, with a
mitochondrial-targeted antioxidant leads to the suppression
of HIF-1a stabilization, a loss in transcriptional activity, and
an arrest of the hypoxia pathway.3.4. Normoxic stabilization of HIF-1a is unaﬀected by MitoQ
Having shown that MitoQ could blockade the hypoxic sta-
bilization of HIF-1a, it was of interest to examine its eﬀects
on non-hypoxic HIF-1a stabilization. To this end, the com-
monly used pharmacological agents for oxygen-independent
stabilization of HIF-1a, cobalt chloride (CoCl2) and desferrox-
amine mesylate (DFO), were examined for a possible associa-
tion with mitochondrial-ROS production. We designed an
experiment wherein Hep3B cells were pre-incubated for 12 h
with MitoQ or vehicle followed by a medium change and addi-
tion of either DFO or CoCl2 (ﬁnal concentration 100 lM) to
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quent 6 h in the presence of these agents. The results, presented
in Fig. 4, show that the presence of either DFO or CoCl2 re-
sulted in the stabilization of HIF-1a after a 6-hour period.
In the same experiment, cells which had been pre-incubated
with 1 lMMitoQ before addition of either DFO or CoCl2 still
retained the ability to express HIF-1a during this time. Thus,
MitoQ had no eﬀect on the ability of DFO and CoCl2 to sta-
bilize HIF-1a under these conditions, and we conclude that
mitochondrial ROS are not involved in this mechanism. This
result, in the context of CoCl2, is in line with recent reports
showing that CoCl2 can deplete intracellular ascorbate stores
resulting in a decreased PHD activity [36], and can also inhibit
the interaction between hydroxylated HIF-1 and pVHL [37].
The mechanism of DFO action on HIF-1 has not been inves-
tigated in detail, but there is a general consensus that DFO, by
accumulating intracellular iron, inhibits the activity of iron-
requiring PHD enzymes.
3.5. Conclusions
In the present study, we have shown that the application of a
targeted mitochondrial antioxidant eliminates the hypoxic gen-
eration of ROS and concurrently reduces HIF-1a levels by
destabilization of the protein, resulting in the loss of transcrip-
tional activity. Evidence that these two processes are linked
arises from our ﬁndings that the destabilizing eﬀect of MitoQ
on HIF-1a only occurred during hypoxic increases in ROS, as
the normoxic levels of HIF-1a in a VHL mutant cell line
(which produces constitutively stabilized HIF-1a) were un-
changed in the presence of MitoQ. We further corroborated
this by showing that pharmacological intervention using
DFO and CoCl2, which are not thought to involve mitochon-
drial ROS, stabilized HIF-1a independently of MitoQ. Re-
cently, a novel pathway of HIF-1a degradation has been
highlighted in which the disruption of mitochondrial function
can lead to oxygen re-location for non-mitochondrial purposes
during hypoxic episodes [34]. We tested whether MitoQ could
be participating in this pathway by measuring oxygen con-
sumption in whole cells in the presence of this antioxidant,
but found that the respiration rate was unchanged. Another
possible mechanism for the MitoQ-induced loss of HIF-1a in
hypoxia could be that, by stabilizing endogenous NO (byFig. 4. Normoxic stabilization of HIF-1a. Hep3B cells at 60%
conﬂuence were treated for 12 h in the presence of 1 lM MitoQ or
vehicle. Next day, cells were washed and re-fed with medium with or
without the addition of 100 lM DFO or 100 lM CoCl2. After a
further incubation for 6 h, cells were collected for Western blot.blocking ROS which react with it), MitoQ addition could lead
to the availability of NO to inhibit complex IV; this could re-
sult in an increase in local concentrations of oxygen for PHD
activity. However, oxygen consumption in our cells was not af-
fected by the NO-synthase inhibitor L-NAME and so we have
no evidence for NO involvement in our system. Undoubtedly,
there is the potential for NO and ROS to interact via mecha-
nisms distinct from oxygen redistribution, for example
peroxynitrite generation leading to nitrotyrosine formation
(reviewed in [38]). Future work will make use of MitoQ to de-
ﬁne these possible contributions.
Considerable data indicate that ROS are an important
means of cellular signaling [39], although the speciﬁc mecha-
nisms whereby ROS accomplish this are still under study.
Many reports in the literature support the notion that an ele-
vation of (mitochondrial?) ROS, during hypoxia, can control
the activation of HIF-1a [11,15,27,40], although there is not
universal agreement [16,17,41]. Our work with a novel targeted
antioxidant strongly suggests that mitochondrial-ROS are
intrinsically linked to HIF-1a expression during hypoxia.
Although we have not investigated the mechanism(s) by which
the ROS signal is transduced to HIF-1a, it is evident from the
literature that multiple protein kinases have the potential to be
involved [42,43]. In light of our study, a potentially instructive
line of analysis, to address signal transduction pathways lead-
ing from mitochondrial ROS, could be to carry out gene
expression analysis in a chosen cell line, under hypoxia, in
the presence or absence of this antioxidant. Clearly, a caveat
of this approach would be that any ROS eﬀects could be by
way of kinase/phosphatase modiﬁcations, and not at the level
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